Market Overview:
The global heparin injection market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of thrombosis, pulmonary embolism, and hemodialysis across the globe. Additionally, rising awareness about the benefits of using heparin injections is also contributing to the growth of this market. Based on type, the global heparin injection market can be segmented into 1,000 USP/mL, 5,000 USP/mL 10 000 USP/mL and 20 000 USP/mL segments. The 1 000USP / mL segment is expected to account for a major share of this market in 2018 owing to its low cost and easy availability as compared to other types of heparin injections. However, with increasing research on novel applications for high-dose heparins such as cancer treatment and prevention of venous thromboembolism (VTE), the 10 000USP / mL segment is projected register highest CAGR during forecast period from 2018to2030 . On basis application ,the globalhe pari n inje ction ma rket can be segmen ted into thro mbos i s,, pul mona ry emboli sm,, h emodi alysi s,, an d ot her s segm ents .
Product Definition:
A heparin injection is a medication that is used to prevent blood clots from forming. It can also be used to dissolve blood clots that have already formed.
1,000 USP/mL:
1000 USP/mL is a concentration used in the preparation of heparin. It is also used as an international unit (IU) in the measurement of heparin potency. 1000 USP/mL contains 1 mg of active ingredient and has a pH value of 7,0.
5,000 USP/mL:
The normal heparin concentration is 300 USP/mL. Concentrations between 180 and 2,000 USP/mL are used for the treatment of anticoagulation disorders such as deep vein thrombosis or pulmonary embolism. The 5,000 USP/mL concentration is used in the treatment of life-threatening coagulation disorders such as disseminated intravascular coagulation (DIC) or acute renal failure (ARF).
Application Insights:
Based on the application, the global heparin injection market is segmented into thrombosis, pulmonary embolism, hemodialysis and others. The thrombosis segment dominated the overall market in terms of revenue share in 2017. This can be attributed to an increase in number of patients suffering from various types of blood clots such as venous thromboembolism (VTE) and deep vein thrombosis (DVT). As per data published by WHO, around 90 million people suffer from VTE annually along with another 300 thousand cases being reported globally each year. Thus rising incidences of these conditions are expected to drive demand for heparin injections over the forecast period.
The use of low molecular weight Heparin (LMWH) has been proven effective than conventional high molecular weight Heparin (HMW-Heparin).
Regional Analysis:
Europe dominated the global market in 2017 owing to the presence of developed healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare expenditure levels. In addition, growing number of product launches is also expected to drive regional growth over the forecast period. Asia Pacific is expected to witness lucrative CAGR during the forecast period due to rising geriatric population base and increasing prevalence of thrombosis & pulmonary embolism that require heparin therapy. Growing medical tourism industry in emerging economies such as India and China are further anticipated boost demand for these products resulting in a higher revenue share by 2030.
The key players operating in this space include Pfizer Inc.; Johnson & Johnson Services Inc.; B Braun Melsungen AG; Actavis Pharma Europe BV; Sanofi SA; and Merck KGaA.
Growth Factors:
- Increasing incidence of venous thromboembolism (VTE) and pulmonary embolism (PE)
- Rising geriatric population susceptible to VTE and PE
- Growing demand for prophylactic anticoagulants to prevent blood clotting in high-risk patients
- Technological advancements in heparin manufacturing process
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Heparin Injection Market Research Report
By Type
1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, 20,000 USP/mL
By Application
Thrombosis,, Pulmonary Embolism, Hemodialysis, Others
By Companies
Pfizer Inc, Wellona Pharma, B. Braun, Gland Pharma Limited, Sagent Pharmaceuticals, Inc, Stanex, Mylan, Rewine Pharmaceutical, Shenzhen Techdow Pharmaceutical Co., Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Heparin Injection Market Report Segments:
The global Heparin Injection market is segmented on the basis of:
Types
1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, 20,000 USP/mL
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Thrombosis,, Pulmonary Embolism, Hemodialysis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc
- Wellona Pharma
- B. Braun
- Gland Pharma Limited
- Sagent Pharmaceuticals, Inc
- Stanex
- Mylan
- Rewine Pharmaceutical
- Shenzhen Techdow Pharmaceutical Co., Ltd
Highlights of The Heparin Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1,000 USP/mL
- 5,000 USP/mL
- 10,000 USP/mL
- 20,000 USP/mL
- By Application:
- Thrombosis,
- Pulmonary Embolism
- Hemodialysis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Heparin Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Heparin is a blood thinner that helps to prevent clots from forming in the blood. It is given as an injection into a vein.
Some of the major players in the heparin injection market are Pfizer Inc, Wellona Pharma, B. Braun, Gland Pharma Limited, Sagent Pharmaceuticals, Inc, Stanex, Mylan, Rewine Pharmaceutical, Shenzhen Techdow Pharmaceutical Co., Ltd.
The heparin injection market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Heparin Injection Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Heparin Injection Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Heparin Injection Market - Supply Chain
4.5. Global Heparin Injection Market Forecast
4.5.1. Heparin Injection Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Heparin Injection Market Size (000 Units) and Y-o-Y Growth
4.5.3. Heparin Injection Market Absolute $ Opportunity
5. Global Heparin Injection Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Heparin Injection Market Size and Volume Forecast by Type
5.3.1. 1,000 USP/mL
5.3.2. 5,000 USP/mL
5.3.3. 10,000 USP/mL
5.3.4. 20,000 USP/mL
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Heparin Injection Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Heparin Injection Market Size and Volume Forecast by Application
6.3.1. Thrombosis,
6.3.2. Pulmonary Embolism
6.3.3. Hemodialysis
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Heparin Injection Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Heparin Injection Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Heparin Injection Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Heparin Injection Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Heparin Injection Demand Share Forecast, 2019-2026
9. North America Heparin Injection Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Heparin Injection Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Heparin Injection Market Size and Volume Forecast by Application
9.4.1. Thrombosis,
9.4.2. Pulmonary Embolism
9.4.3. Hemodialysis
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Heparin Injection Market Size and Volume Forecast by Type
9.7.1. 1,000 USP/mL
9.7.2. 5,000 USP/mL
9.7.3. 10,000 USP/mL
9.7.4. 20,000 USP/mL
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Heparin Injection Demand Share Forecast, 2019-2026
10. Latin America Heparin Injection Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Heparin Injection Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Heparin Injection Market Size and Volume Forecast by Application
10.4.1. Thrombosis,
10.4.2. Pulmonary Embolism
10.4.3. Hemodialysis
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Heparin Injection Market Size and Volume Forecast by Type
10.7.1. 1,000 USP/mL
10.7.2. 5,000 USP/mL
10.7.3. 10,000 USP/mL
10.7.4. 20,000 USP/mL
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Heparin Injection Demand Share Forecast, 2019-2026
11. Europe Heparin Injection Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Heparin Injection Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Heparin Injection Market Size and Volume Forecast by Application
11.4.1. Thrombosis,
11.4.2. Pulmonary Embolism
11.4.3. Hemodialysis
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Heparin Injection Market Size and Volume Forecast by Type
11.7.1. 1,000 USP/mL
11.7.2. 5,000 USP/mL
11.7.3. 10,000 USP/mL
11.7.4. 20,000 USP/mL
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y GrowthProjections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Heparin Injection Demand Share, 2019-2026
12. Asia Pacific Heparin Injection Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Heparin Injection Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Heparin Injection Market Size and Volume Forecast by Application
12.4.1. Thrombosis,
12.4.2. Pulmonary Embolism
12.4.3. Hemodialysis
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Heparin Injection Market Size and Volume Forecast by Type
12.7.1. 1,000 USP/mL
12.7.2. 5,000 USP/mL
12.7.3. 10,000 USP/mL
12.7.4. 20,000 USP/mL
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Heparin Injection Demand Share, 2019-2026
13. Middle East & Africa Heparin Injection Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Heparin Injection Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Heparin Injection Market Size and Volume Forecast by Application
13.4.1. Thrombosis,
13.4.2. Pulmonary Embolism
13.4.3. Hemodialysis
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Heparin Injection Market Size and Volume Forecast by Type
13.7.1. 1,000 USP/mL
13.7.2. 5,000 USP/mL
13.7.3. 10,000 USP/mL
13.7.4. 20,000 USP/mL
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Heparin Injection Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Heparin Injection Market: Market Share Analysis
14.2. Heparin Injection Distributors and Customers
14.3. Heparin Injection Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Wellona Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. B. Braun
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Gland Pharma Limited
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sagent Pharmaceuticals, Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Stanex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Mylan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Rewine Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shenzhen Techdow Pharmaceutical Co., Ltd
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
